KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes...<< Prices as on Jun 20, 2024 - 3:59PM >>  ABB India 8542.9  [ 0.02% ]  ACC 2626.9  [ 0.26% ]  Ambuja Cements 659.15  [ -1.12% ]  Asian Paints Ltd. 2918  [ 0.88% ]  Axis Bank Ltd. 1237.9  [ 0.95% ]  Bajaj Auto 9622.1  [ -0.68% ]  Bank of Baroda 285.2  [ 0.48% ]  Bharti Airtel 1381.15  [ -0.86% ]  Bharat Heavy Ele 293.4  [ -1.21% ]  Bharat Petroleum 626.3  [ 1.66% ]  Britannia Ind. 5384.8  [ 0.46% ]  Cipla 1547.95  [ -0.73% ]  Coal India 483.15  [ 1.04% ]  Colgate Palm. 2859.6  [ -1.20% ]  Dabur India 600.7  [ 0.38% ]  DLF Ltd. 874.4  [ 1.70% ]  Dr. Reddy's Labs 5973  [ 0.31% ]  GAIL (India) 218.55  [ 1.02% ]  Grasim Inds. 2500  [ 2.14% ]  HCL Technologies 1446  [ 0.07% ]  HDFC 2729.95  [ -0.62% ]  HDFC Bank 1669  [ 0.66% ]  Hero MotoCorp 5513.2  [ -2.32% ]  Hindustan Unilever L 2478.1  [ 0.85% ]  Hindalco Indus. 676.75  [ 2.16% ]  ICICI Bank 1156.8  [ 1.05% ]  IDFC L 123.75  [ 2.19% ]  Indian Hotels Co 638.3  [ 3.46% ]  IndusInd Bank 1529  [ -0.03% ]  Infosys L 1515.3  [ 0.26% ]  ITC Ltd. 423.35  [ -0.08% ]  Jindal St & Pwr 1056.65  [ 0.93% ]  Kotak Mahindra Bank 1765.05  [ 0.96% ]  L&T 3597.1  [ 0.19% ]  Lupin Ltd. 1555.1  [ -1.12% ]  Mahi. & Mahi 2870.7  [ -2.10% ]  Maruti Suzuki India 12143.9  [ -0.75% ]  MTNL 41.71  [ -1.00% ]  Nestle India 2538  [ 0.51% ]  NIIT Ltd. 104.6  [ 2.25% ]  NMDC Ltd. 273.2  [ 4.24% ]  NTPC 357.9  [ -1.26% ]  ONGC 271.85  [ 0.11% ]  Punj. NationlBak 128.5  [ 0.19% ]  Power Grid Corpo 324.6  [ -0.90% ]  Reliance Inds. 2946.4  [ 1.00% ]  SBI 843.8  [ -1.03% ]  Vedanta 470.25  [ 4.86% ]  Shipping Corpn. 273.15  [ -0.51% ]  Sun Pharma. 1470.45  [ -2.24% ]  Tata Chemicals 1153.2  [ 4.23% ]  Tata Consumer Produc 1105.65  [ -0.04% ]  Tata Motors 978.1  [ 0.07% ]  Tata Steel 182.35  [ 1.28% ]  Tata Power Co. 444.2  [ 0.43% ]  Tata Consultancy 3786.6  [ -0.38% ]  Tech Mahindra 1392.1  [ 0.79% ]  UltraTech Cement 10951.5  [ -0.36% ]  United Spirits 1269  [ -0.23% ]  Wipro 490.5  [ -1.03% ]  Zee Entertainment En 155.55  [ 0.78% ]  

Company Information

Indian Indices

  • Loading....

Global Indices

  • Loading....


  • Loading....


20 June 2024 | 04:06

Industry >> Pharmaceuticals

Select Another Company

ISIN No INE044A01036 BSE Code / NSE Code 524715 / SUNPHARMA Book Value (Rs.) 265.35 Face Value 1.00
Bookclosure 09/02/2024 52Week High 1639 EPS 39.91 P/E 36.86
Market Cap. 352942.17 Cr. 52Week Low 977 P/BV / Div Yield (%) 5.54 / 0.92 Market Lot 1.00
Security Type Other


You can view the entire text of Notes to accounts of the company for the latest year
Year End :2023-03 

Nature and purpose of each reserve

Capital reserve - During amalgamation / merger / acquisition, the excess of net assets taken, over the consideration paid, if any, is treated as capital reserve.

Securities premium - The amount received in excess of face value of the equity shares is recognised in securities premium. In case of equity-settled share based payment transactions, the difference between fair value on grant date and nominal value of share is accounted as securities premium. It is utilised in accordance with the provisions of the Companies Act, 2013.

Amalgamation reserve - The reserve was created pursuant to scheme of amalgamation in earlier years.

Capital redemption reserve - The Company has recognised capital redemption reserve on buyback of equity shares from its retained earnings. The amount in capital redemption reserve is equal to nominal amount of the equity shares bought back.

General reserve: The reserve arises on transfer portion of the net profit pursuant to the earlier provisions of Companies Act, 1956. Mandatory transfer to general reserve is not required under the Companies Act, 2013.

Equity instrument through OCI - The Company has elected to recognise changes in the fair value of certain investment in equity instrument in other comprehensive income. This amount will be reclassified to retained earnings on derecognition of equity instrument.

Debt instrument through OCI - This represents the cumulative gain and loss arising on fair valuation of debt instruments measured through other comprehensive income. This will be reclassified to statement of profit or loss on derecognition of debt instrument.

Foreign currency translation reserve - Exchange differences relating to the translation of the results and the net assets of the Company's foreign operations from their functional currencies to the Company's presentation currency (i.e. ^) are recognised directly in the other comprehensive income and accumulated in foreign currency translation reserve. Exchange difference in the foreign currency translation reserve are reclassified to statement of profit or loss account on the disposal of the foreign operation.

Effective portion of cash flow hedges - The cash flow hedging reserve represents the cumulative effective portion of gains or losses arising on changes in fair value of designated portion of hedging instruments entered into for cash flow hedges.

The cumulative gain or loss recognised and accumulated under the cash flow hedge reserve will be reclassified to profit or loss only when the hedged transaction affects the profit or loss, or included as a basis adjustment to the non-financial hedged item.

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date.

Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly.

Level 3 inputs are unobservable inputs for the asset or liability.

The investments included in Level 3 of fair value hierarchy have been valued using the cost approach to arrive at their fair value. The cost of unquoted investments approximates the fair value because there is wide range of possible fair value measurements and the costs represents estimate of fair value within that range.

# These investments in equity instruments are not held for trading. Upon the application of Ind AS 109, the Company has chosen to designate these investments in equity instruments at fair value through other comprehensive income.

There were no transfers between Level 1 and 2 in the periods.

The management considers that the carrying amount of financial assets and financial liabilities carried at amortised cost approximates their fair value.


The Company's activities expose it to a variety of financial risks, including market risk, credit risk and liquidity risk. The Company's risk management assessment and policies and processes are established to identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor such risks and compliance with the same. Risk assessment and management policies and processes are reviewed regularly to reflect changes in market conditions and the Company's activities.

Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's receivables from customers, loans and investments. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of counterparty to which the Company grants credit terms in the normal course of business.


The Company limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating. The Company does not expect any significant losses from non-performance by these counter-parties, and does not have any significant concentration of exposures to specific industry sectors or specific country risks.

Other than trade receivables, the Company has recognised an allowance of ? 15.3 Million (March 31, 2022: ? 15.3 Million) against past due loans including interest and ? 500 Million (March 31, 2022: ? 500.0 Million) of other receivables based on assessment regarding its future recoverability.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by ensuring, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risk to the Company's reputation.

The Company has unutilised working capital lines from banks of ? 35,780.0 Million as on March 31, 2023 (March 31, 2022:

? 36,030.0 Million).

Market risk

Market risk is the risk of loss of future earnings, fair values or future cash flows that may result from adverse changes in market rates and prices (such as interest rates, foreign currency exchange rates and commodity prices) or in the price of market risk-sensitive instruments as a result of such adverse changes in market rates and prices. Market risk is attributable to all market risk-sensitive financial instruments, all foreign currency receivables and payables and all short term and long-term debt. The Company is exposed to market risk primarily related to foreign exchange rate risk, interest rate risk and the market value of its investments. Thus, the Company's exposure to market risk is a function of investing and borrowing activities and revenue generating and operating activities in foreign currencies.

Foreign exchange risk

The Company's foreign exchange risk arises from its foreign operations, foreign currency revenues and expenses, (primarily in US Dollars, Euros, South African Rand, Brazilian Real and Russian Rouble). As a result, if the value of the Indian rupee appreciates relative to these foreign currencies, the Company's revenues and expenses measured in Indian rupees may decrease or increase and vice-versa. The exchange rate between the Indian rupee and these foreign currencies have changed substantially in recent periods and may continue to fluctuate substantially in the future. Consequently, the Company uses both derivative and non-derivative financial instruments, such as foreign exchange forward contracts, option contracts, currency swap contracts and foreign currency financial liabilities, to mitigate the risk of changes in foreign currency exchange rates in respect of its highly probable forecasted transactions and recognised assets and liabilities.

b) Sensitivity

For the years ended March 31, 2023 and March 31, 2022, every 5% strengthening in the exchange rate between the Indian rupee and the respective currencies for the above mentioned financial assets/liabilities would (decrease) / increase the Company's profit and (decrease) / increase the Company's equity by approximately ? (2,685.5) Million and ? (651.9) Million respectively. A 5% weakening of the Indian rupee and the respective currencies would lead to an equal but opposite effect.

In management's opinion, the sensitivity analysis is unrepresentative of the inherent foreign exchange risk because the exposure at the end of the reporting period does not reflect the exposure during the year.

c) Derivative contracts

The Company is exposed to exchange rate risk that arises from its foreign exchange revenues and expenses, primarily in US Dollars, Euros, South African Rand, Brazilian Real and Russian Rouble. The Company uses foreign currency forward contracts, foreign currency option contracts and currency swap contracts (collectively, “derivatives”) to mitigate its risk of changes in foreign currency exchange rates. The counterparty for these contracts is generally a bank or a financial institution.

Hedges of highly probable forecasted transactions

The Company designates its derivative contracts that hedge foreign exchange risk associated with its highly probable forecasted transactions as cash flow hedges and measures them at fair value. The effective portion of such cash flow hedges is recorded in other comprehensive income, and re-classified in the income statement as revenue in the period corresponding to the occurrence of the forecasted transactions. The ineffective portion of such cash flow hedges is immediately recorded in the statement of profit and loss.

In respect of the aforesaid hedges of highly probable forecasted transactions, the Company has recorded a net loss of ? 192.4 Million for the year ended March 31, 2023 and net loss of ? 492.4 Million for the year ended March 31, 2022 in other comprehensive income. The Company also recorded hedges as a component of revenue, loss of ? 1,076.9 Million for the year ended March 31, 2023 and gain of ? 1,128.3 Million for the year ended March 31, 2022 on occurrence of forecasted sale transaction.

Changes in the fair value of forward contracts and option contracts that economically hedge monetary assets and liabilities in foreign currencies, and for which no hedge accounting is applied, are recognised in the statement of profit and loss. The changes in fair value of the forward contracts and option contracts, as well as the foreign exchange gains and losses relating to the monetary items, are recognised in the statement of profit and loss.

Interest rate risk

As at March 31, 2023 and March 31, 2022, the Company has loan facilities which are either on fixed interest rates or are managed by interest rate swaps. Hence the Company is not exposed to interest rate risk.

Commodity rate risk

Exposure to market risk with respect to commodity prices primarily arises from the Company's purchases and sales of active pharmaceutical ingredients, including the raw material components for such active pharmaceutical ingredients. These are commodity products, whose prices may fluctuate significantly over short periods of time. The prices of the Company's raw materials generally fluctuate in line with commodity cycles, although the prices of raw materials used in the Company's active pharmaceutical ingredients business are generally more volatile. Cost of raw materials forms the largest portion of the Company's cost of revenues. Commodity price risk exposure is evaluated and managed through operating procedures and sourcing policies. As of March 31, 2023, the Company had not entered into any material derivative contracts to hedge exposure to fluctuations in commodity prices.

NOTE: 47 EMPLOYEE BENEFIT PLANS Defined contribution plan

Contributions are made to Regional Provident Fund (RPF), Family Pension Fund, Employees State Insurance Scheme (ESIC) and other Funds which covers all regular employees. While both the employees and the Company make predetermined contributions to the Provident Fund and ESIC, contribution to the Family Pension Fund and other Statutory Funds are made only by the Company. The contributions are normally based on a certain percentage of the employee's salary. Amount recognised as expense in respect of these defined contribution plans, aggregate to ? 951.9 Million (March 31, 2022: ? 872.1 Million).

Defined benefit plana) Gratuity

In respect of Gratuity, a defined benefit plan, contributions are made to LIC's Recognised Group Gratuity Fund Scheme. It is governed by the Payment of Gratuity Act, 1972. Under the Gratuity Act, employees are entitled to specific benefit at the time of retirement or termination of the employment on completion of five years or death while in employment. The level of benefit provided depends on the member's length of service and salary at the time of retirement/ termination age. Provision for gratuity is based on actuarial valuation done by an independent actuary as at the year end. Each year, the Company reviews the level of funding in gratuity fund and decides its contribution. The Company aims to keep annual contributions relatively stable at a level such that the fund assets meets the requirements of gratuity payments in short to medium term.

b) Pension fund

The Company has an obligation towards pension, a defined benefit retirement plan, with respect to certain employees, who had already retired before March 01, 2013 and will continue to receive the pension as per the pension plan.

c) COVID-19 Employee children education support

The Company have undertaken an obligation to provide financial support towards education expenses of the children of those employees who have lost their lives due to the COVID-19 pandemic.


These plans typically expose the Company to actuarial risks such as: investment risk, interest rate risk, longevity risk and salary risk.

i) Investment risk - The present value of the defined benefit plan liability is calculated using a discount rate determined by reference to the market yields on government bonds denominated in Indian Rupees. If the actual return on plan asset is below this rate, it will create a plan deficit. However, the risk is partially mitigated by investment in LIC managed fund.

ii) Interest rate risk - A decrease in the bond interest rate will increase the plan liability. However, this will be partially offset by an increase in the return on the plan's debt investments.

iii) Longevity risk - The present value of the defined benefit plan liability is calculated by reference to the best estimate of the mortality of plan participants both during and after their employment. An increase in the life expectancy of the plan participants will increase the plan's liability.

iv) Salary risk - The present value of the defined benefit plan liability is calculated by reference to the future salaries of plan participants. As such, an increase in the salary of the plan participants will increase the plan's liability.

Other long term benefit plan

Actuarial Valuation for compensated absences is done as at the year end and the provision is made as per Company policy with corresponding charge to the statement of profit and loss amounting to ? 234.8 Million [March 31, 2022: ? 539.5 Million] and it covers all regular employees. Major drivers in actuarial assumptions, typically, are years of service and employee compensation.

Obligation in respect of defined benefit plan and other long term employee benefit plans are actuarially determined as at the year end using the ‘Projected Unit Credit' method. Gains and losses on changes in actuarial assumptions relating to defined benefit obligation are recognised in other comprehensive income whereas gains and losses in respect of other long term employee benefit plans are recognised in profit or loss.

Contract assets are initially recognised for revenue from sale of goods. Contract liabilities are on account of the upfront revenue received from customer for which performance obligation has not yet been completed.

The performance obligation is satisfied when control of the goods or services are transferred to the customers based on the contractual terms. Payment terms with customers vary depending upon the contractual terms of each contract.

The Company has recognised revenue of ? 3,239.1 Million from the amounts included under advance received from customers at the beginning of the year.

NOTE: 55

1 Intangible assets consisting of trademarks, designs, technical knowhow, non-compete fees and other intangible assets are available to the Company in perpetuity. The amortisable amount of intangible assets is arrived at based on the management's best estimates of useful lives of such assets after due consideration as regards their expected usage, the product life cycles, technical and technological obsolescence, market demand for products, competition and their expected future benefits to the Company.

2 Exceptional items includes

a) The Company has recognised an impairment charge of ? 29,377.9 Million in relation to the Company's investment in equity and preference shares of Sun Pharma Holdings, Mauritius, (“SPH”) amounting to ? 127,673.7 Million in the standalone financial statements for the year ended March 31, 2023.

Investment by SPH in its step down subsidiaries, primarily in Taro, are determined as CGU as they derive their revenue from pharmaceutical products.

The recoverable value of CGU represents its Value-in-use. The Value-in-use is determined using the discounted cash flow method on projections using a post-tax rate of 8% while the post-tax discount rate in previous year was 7%. As per management assessment, the fair valuation of the CGU is lower than its carrying value which is on account of various reasons including but not limited to pricing pressure in the United States, delays in launch of generic products, etc. Accordingly, the valuation gap has been addressed by impairment to that extent.

b) Standalone financial statements for the year ended March 31, 2022 include a charge of ? 1,655.7 Million towards impairment of an acquired intangible asset under development.

c) The Company and certain of its subsidiaries were defendants in a number of class action lawsuits brought by purchasers and payors in the U.S. alleging violation of antitrust laws with respect to its ANDAs for Valganciclovir, Valsartan and Esomeprazole. The cases were transferred to the U.S. District Court for the District of Massachusetts for coordinated proceedings. With a view to resolve the dispute and avoid uncertainty, a settlement without any admission of guilt or violation of any statute, law, rule or regulation, or of any liability

or wrongdoing was reached with all of the plaintiff classes on March 23, 2022, for a total settlement amount of USD 485 Million of which USD 210 Million was borne by the Company along with its related legal charges of USD 8.3 Million pertaining to this lawsuit (equivalent to ? 16,549.6 Million inclusive of legal charges). The charge for the settlement was considered in the year ended March 31, 2022. The court granted final approval to the settlement and dismissed all of the cases in September 2022.

d) Consequent to the settlement of lawsuit mentioned in “c” above, during the year ended March 31, 2022, the Company has reassessed the expected timing of utilisation of Minimum Alternate Tax (MAT) credit and based on this reassessment written off a MAT credit of ? 4,406.0 Million and disclosed the charge as an exceptional item.

3. Since the US FDA import alert at Karkhadi facility in March 2014, the Company has remained fully committed to implement all corrective measures to address the observations made by the US FDA with the help of third-party consultants. The Company had completed all the action items to address the US FDA warning letter observations issued in May 2014. The Company does not intend to use the Karkhadi facility for drug product manufacturing for the U.S. market. The contribution of this facility to Company's revenues was negligible.

4. The US FDA, on January 23, 2014, had prohibited using API manufactured at Toansa facility for manufacture of finished drug products intended for distribution in the U.S. market. Consequentially, the Toansa manufacturing facility was subject to certain provisions of the consent decree of permanent injunction entered in January 2012 by erstwhile Ranbaxy Laboratories Ltd. (which was merged with Sun Pharmaceutical Industries Ltd. in March 2015). In addition, the United States Attorney's Office for the District of New Jersey (US DOJ) had also issued an administrative subpoena, dated March 13, 2014, seeking information. The Company has fully cooperated and provided the requisite information to the US DOJ. All the Drug Master Files (DMF) from Toansa Facility for the U.S. market have been withdrawn, and the Company does not intend to use the facility for the U.S. market.

5. The Halol facility was placed under import alert in December 2022. US FDA has exempted 14 products from import alert, subject to certain conditions. Previously, the facility was inspected by US FDA in May 2022 and the inspection was classified as Official Action Indicated (OAI) in August 2022. The Company is in communication with the US FDA to resolve the outstanding issues underlying OAI status and import alert.

6. In September 2013, the US FDA had put the Mohali facility under import alert, and it was also subjected to certain provisions of the consent decree of permanent injunction entered in January 2012 by erstwhile Ranbaxy Laboratories Ltd. (which was merged with Parent Company in March 2015). In March 2017, the US FDA lifted the import alert

and indicated that the facility was in compliance with the requirements of cGMP provisions mentioned in the consent decree. The Mohali facility completed the five-year, post-certification provisions as required by the consent decree. The August 2022 US FDA inspection of Mohali facility was classified as Official Action Indicated (OAI) and subsequently, in April 2023, the US FDA issued a Non-Compliance letter to the Mohali facility. As a result, US FDA has directed the Company to take certain corrective actions at the Mohali facility before releasing further final product batches into the US. These actions include, among others, retaining an independent cGMP expert to conduct batch certifications of drugs manufactured at the Mohali facility and for shipment to the U.S. market.

7. In accordance with Ind AS 108 “Operating Segments”, segment information has been given in the consolidated Ind AS financial statements, and therefore, no separate disclosure on segment information is given in these standalone financial statements.

8. During the year ended March 31, 2022, the Company had acquired additional 11.28% stake in Zenotech Laboratories Limited (Zenotech), a subsidiary of the Company, from Daiichi Sankyo Company Ltd. for a total consideration of

? 53.2 Million pursuant to a share purchase agreement. Post this acquisition, the Company's shareholding in Zenotech increased from 57.56 % to 68.84%.

9. The date of implementation of the Code on Wages 2019 and the Code on Social Security, 2020 is yet to be notified by the Government. The Company will assess the impact of these Codes and give effect in the standalone financial statements when the Rules / Schemes thereunder are notified.

10. Corporate social responsibility (CSR)

As per section 135 of the Companies Act, 2013, the Company is required to spend at least 2% of its average net profits for the immediately preceding three financial years on corporate social responsibility activities. The CSR Committee of the Company monitors the CSR activities and the projects are undertaken in pursuance of the Company's CSR Policy and the Annual Action Plan. Company's Annual Action Plan for the financial year 2022-23 covered CSR activities in the areas - Healthcare; Education; Environment Conservation; Drinking Water Project; Disaster Relief and Rural Development Programme.

11. On March 01, 2023, the Company disclosed an information security incident that impacted some of the Company's IT assets. The Company promptly took steps to contain and remediate the impact of the information security incident, including employing appropriate containment protocols to mitigate the threat, employing enhanced security measures and utilising global cyber security experts to ensure the integrity of the Company's IT systems' infrastructure and data. As part of the containment measures, the Company proactively isolated its network and initiated recovery procedures. As a result of these measures, certain business operations were also impacted.

Based on the Company's investigation, the Company currently believes that the incident's effects on its IT system include a breach of certain file systems and the theft of Company data and personal data. A ransomware group has claimed responsibility for this incident.

The Company has since strengthened its cybersecurity infrastructure and is in the process of implementing improvements to its cyber and data security systems to safeguard against such risks in the future. The Company is also implementing certain long-term measures to augment its security controls systems across the organization. The Company worked with legal counsel across relevant jurisdictions to notify applicable regulatory and data protection authorities, where considered required, and the Company believes there is no material legal non-compliance by the Company on account of the information security incident. The Company believes that all known impacts on its standalone financial statements for the year ended March 31, 2023 on account of this incident have been considered.

12. The Scheme of Amalgamation and Merger of Sun Pharma Global FZE (“the Transferor”), with the Company (“the Scheme”), inter-alia envisaged merger of the transferor into the Company. The scheme was approved by Hon'ble National Company Law Tribunal, Ahmedabad Bench on August 31, 2021 and became effective on October 01, 2021 upon completion of all the formalities.

Consequent to the amalgamation and merger prescribed by the Scheme, all the assets and liabilities of the transferor were transferred to and vested in the Company with effect from January 01, 2020 (“the Appointed Date”). The amalgamation was accounted under the “pooling of interest” method prescribed under Ind AS 103 - Business Combinations, as prescribed by the Scheme.

Accordingly all the assets, liabilities, and other reserves of the transferor as on January 01, 2020 were transferred to the Company as per the Scheme. As prescribed by the Scheme no consideration was paid as the transferor is a indirect wholly owned subsidiary of the Company. The resultant difference between the book value of assets and liabilities taken-over as on the appointed date on the existing carrying value has been credited to capital reserve amounting to ? 273.3 Million. Further, as prescribed in the scheme approved by the NCLT , the Company had recorded an impact of impairment in relation to the equity shares held by the Company in the subsidiary through which the Company holds equity shares of the Transferor amounting to ? 31,590.0 Million which has been debited to capital reserve account. Also, any gain or loss on translation of assets and liabilities to functional currency (i.e. ^) till the date of order was credited or debited to foreign currency translation reserve.

13. As part of the ongoing simplification of the group structure in India, the Board of Directors of the Company at its meeting held on May 30, 2022, approved the Scheme of Amalgamation for the merger of Wholly-owned Subsidiaries, Sun Pharmaceutical Medicare Limited, Green Eco Development Centre Limited, Faststone Mercantile Company Private Limited, Realstone Multitrade Private Limited and Skisen Labs Private Limited (collectively “Transferor Companies”), with Sun Pharmaceutical Industries Limited (“Transferee Company”) to be effective from such date as may be decided under the authorisation by the Board of Directors of the Transferor Companies and the Board of Directors of the Transferee Company and / or such other date as may be approved by the National Company Law Tribunal pursuant to the provisions of Sections 230 to 232 of Companies Act, 2013 and other relevant provisions of the Companies Act, 2013 and rules framed thereunder.

15. No proceeding have been initiated or pending against the Company under the Benami Transactions (Prohibitions) Act, 1988 (45 of 1988) and the Rules made thereunder.

16. The Company has not traded or invested in crypto currency or virtual currency during the financial year.

17. The Company has not granted any loans or advances in the nature of loans to promoters, directors and KMPs, either severally or jointly with any other person. No trade or other receivable are due from directors of the company either severally or jointly with any other person.

18. The Company does not have any transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961)

19. The Company has not been sanctioned working capital limits from banks or financial institutions during any point of time of the year on the basis of security of current assets.

20. The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.

21. No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities (“Intermediaries”), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries. However , the Company, as a part of its treasury operations, invests/advances loans to fund the operations of its subsidiaries/associates/ joint venture which have further utilised these funds for their general corporate purposes/ working capital, etc. within the consolidated group of the Company and in the ordinary course of business. These transactions are done on arms length basis following a due approval process.

Further, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities (“Funding Parties”), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

24. Relationship with Struck off Companies

The Company does not have any transactions and balances with companies which are struck off except shares held by 10 shareholders holding 11,889 shares (March 31, 2022 - 8 shareholders holding 7,653 shares) having face value of ? 1 per share.

25. Figures for previous year have been regrouped / reclassified wherever considered necessary.